Title

CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.

Document Type

Article

Publication Date

1-1-2019

Identifier

PMCID: PMC6479273 [Available on 2020-01-01] DOI: 10.2217/pgs-2018-0143

Abstract

Warfarin continues to be the mainstay therapy for preventing thrombus formation. Although pharmacogenetic algorithms have shown higher predictability of the optimal warfarin dose and lower occurrence of bleeding episodes, they often do not include ethno-specific genetic variants relevant to non-Europeans. This case report describes a rare missense variant at exon 9 of CYP2C9 (rs202201137; c.1370A>G transition; p.Asn457Ser) found in a Puerto Rican patient with low warfarin dose requirements (3 mg/day). The haplotype characterized by two amino acid changes, Asn457Ser and Arg144Cys (rs1799853; c.430C>T), has been designated CYP2C9*61 by the Pharmacogene Variation Consortium. According to prediction scores assessed with the Combined Annotation Dependent Depletion tool, CYP2C9*61 (p.Asn457Ser) was classified as nondeleterious, therefore its impact on CYP2C9 enzymatic activity cannot be postulated.

Journal Title

Pharmacogenomics

Volume

20

Issue

1

First Page

3

Last Page

8

MeSH Keywords

Warfarin/administration and dosage; Hispanic Americans; Haplotypes; High-Throughput Nucleotide Sequencing; Pharmacogenetics

Keywords

Hispanics; anticoagulation; haplotype; next-generation sequencing; pharmacogenetics (PGx); warfarin

Share

COinS